The IDT Australia (ASX:ITD) share price is soaring on news the company has been asked whether it is capable of producing COVID-19 vaccines.
The post Why COVID-19 is launching the IDT Australia (ASX:IDT) share price 65% appeared first on The Motley Fool Australia. –
IDT Australia Limited (ASX: ITD) shares are soaring today after the company announced it has been approached by the Australian Government to assess the feasibility of producing COVID-19 vaccines. At the time of writing, the IDT share price is rocketing 64.86% to 30.5 cents.
The pharmaceutical company, known for producing medical cannabis products, is assessing whether its facilities would be suitable to manufacture the vaccines.
Let’s take a closer look.
Vaccine production ramps up
IDT Australia announced today it has been contacted by the Australian Government Department of Health. The company claims the department was inquiring about whether IDT Australia’s Melbourne-based sterile facility could be used to supplement manufacturing of COVID-19 vaccines.
Currently, the Federal Health Department states that CSL Limited‘s (ASX: CSL) Melbourne facility is the only manufacturer of the Oxford-AstraZeneca vaccine in Australia. It also states that the Oxford-AstraZeneca vaccine will be the only one to be produced in Australia.
More about IDT Australia
IDT, Institute of Drug Technology, is a commercial-scale pharmaceutical manufacturing and production company.
It specialises in manufacturing active pharmaceutical ingredients and finished form doses.
IDT Australia began manufacturing medicinal cannabis products in 2019 and, according to the company, it operates a leading facility in the medical cannabis manufacturing space.
IDT Australia share price snapshot
Following today’s gains, the IDT share price is now trading at its highest levels since May 2016.
Over the past year, IDT shares have risen by around 210%. The company’s shares are also up by around 60% year to date however all these gains have occurred today.
IDT Australia has a market capitalisation of around $44.4 million with approximately 240 million shares outstanding.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Are COVID-19 vaccine worries affecting the CSL (ASX:CSL) share price?
- Qantas (ASX:QAN) share price slips on employee payment news
- 2 strong blue chip ASX shares rated as buys by brokers
- Bring your portfolio to life with these fantastic ASX healthcare shares
- Temperature check: How is the CSL (ASX:CSL) share price faring today?
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.